Navigation Links
Drug Shields Mice From Emphysema
Date:12/22/2008

Experimental approach seemed to protect the animals from smoke's harmful effects, researchers say

MONDAY, Dec. 22 (HealthDay News) -- In experiments in mice, scientists have shown that a new drug may protect the animals from the respiratory damage caused by cigarettes.

The finding holds out hope for patients with chronic obstructive pulmonary disease (COPD) -- a chronic progressive lung disease involving both emphysema and chronic obstructive bronchitis.

COPD, most commonly linked to smoking, is the fourth leading cause of death in the United States and there are no effective treatments.

"Our previous studies have shown that there is a defect in Nrf2 -- a master regulator of antioxidant and detoxifying pathways -- in the lungs of COPD patients that may be involved in the severity of this disease," explained lead researcher Shyam Biswal, an associate professor at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

In this study, the researchers used a novel drug molecule called CDDO-imidazole (CDDO-Im) to curb the progression of the disease by targeting the Nrf2 pathway.

"The result demonstrates that this strategy is effective in the preclinical model of emphysema," Biswal said.

The report is published in this week's online edition of the Proceedings of the National Academy of Sciences.

For the study, Biswal's team exposed mice to cigarette smoke for six months. Half the mice were treated with CDDO-Im while the other animals were not.

The researchers found that mice treated with CDDO-Im did not develop heart and lung damage while their untreated counterparts did.

Dr. Norman Edelman, chief medical officer of the American Lung Association, believes the new approach to treating COPD could be effective.

"There have been several studies identifying disrupted oxidant defense systems in COPD," Edelman said. "What's different about this one is that a control point for a whole group of oxidant defenses has been identified in rather elegant studies. Thus, if a therapy up-regulating this site were developed it would be more likely to be effective in COPD," he said.

This study provides hope that strategies aimed at targeting the Nrf2 pathway might be effective in inhibiting the development of emphysema, Biswal said.

"Future studies will be done in COPD patients to test the strategy of targeting Nrf2, to test the efficacy in reducing the burden of this debilitating disease," Biswal said.

However, Dr. Bartolome R. Celli, chief of pulmonary care at St. Elizabeth's Medical Center in Boston, said the jury is still out on the effectiveness of this approach.

"It is an interesting and intriguing study," Celli said. "However, from the experiments in mice to reality in humans there usually is a great distance," he said.

There is consensus that oxidative stress associated with cigarette smoking is important in COPD, so balancing oxidative stress with antioxidants makes sense, Celli said.

"This study takes it one step further by testing the hypothesis in vivo [animals]," according to Celli. "Let's wait for the translation into humans," he said.

More information

For more information on emphysema, visit the U.S. National Library of Medicine .



SOURCES: Shyam Biswal, Ph.D., associate professor, Johns Hopkins Bloomberg School of Public Health, Baltimore; Bartolome R. Celli, M.D., chief, pulmonary care, St. Elizabeth's Medical Center, Boston; Norman Edelman, M.D., chief medical officer, American Lung Association; Dec. 22-26, 2008, Proceedings of the National Academy of Sciences, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Football helmet shields can protect against a kick in the face
2. Col. Robert E. Shields Joins Palmetto GBAs Board of Directors
3. Appropriate timing in the use of breast shields in children can further reduce MDCT radiation dose
4. Potential treatment option for severe emphysema under study
5. Young Pop Stars Emphysema Startles Experts
6. Acne Drug Prevents Tissue Damage From Emphysema
7. Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers
8. Researchers at Pulmonary Associates to study airway bypass procedure for severe emphysema
9. New York Methodist Hospital to study airway bypass treatment for emphysema
10. Researchers at Peoria Pulmonary Associates to study airway bypass procedure for emphysema
11. Lung Bypass Could Fight Emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Shields Mice From Emphysema
(Date:12/6/2016)... ... December 06, 2016 , ... It can be argued that people these days ... members as they do for their human friends and family. As pets have ... highest quality and most innovative pet products has also increased. , For ...
(Date:12/6/2016)... IN (PRWEB) , ... December 06, 2016 , ... ... benefits advisory organization, is proud to announce it has added CXC Solutions (CXC) ... benefits management solutions. These solutions are tailored to help benefits advisors reduce ...
(Date:12/6/2016)... ... 2016 , ... METTLER TOLEDO has launched its online ... papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user manuals, ... webinars and videos available online, visit the METTLER TOLEDO Expertise Library . ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... fascinating recount of a powerful woman's story of sacrifice and enlightenment. ... of published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) was ... for their industry leading training methods that engage their associates and link their ... global elite in employer-sponsored training and development programs. , “The 2017 Training Top ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LONDON , Dec. 5, 2016 Spain ... GlobalData,s new report, "Spain Glaucoma Surgery Devices Market ... Spain Glaucoma Surgery Devices market. The report provides value, ... average prices (USD) within market segements - Canaloplasty Micro ... provides company shares and distribution shares data for each ...
(Date:12/5/2016)... , Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., ... presented data from two Phase I trials evaluating ... the 58th annual meeting of the American Society ... California . The two datasets show encouraging ... myeloid leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell ...
(Date:12/5/2016)... 2016  Pennsylvania Physician General Dr. Rachel Levine ... Gary Tennis today filled prescriptions for naloxone, a ... York to demonstrate how anyone ... as a prescription to acquire naloxone at any pharmacy ... remember that any Pennsylvanian can walk up to their ...
Breaking Medicine Technology: